MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598045 | Name: Tirofiban
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tirofiban is an antiplatelet drug. It belongs to a class of antiplatelet named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead. Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Chemical Structure

Tirofiban
CAS#144494-65-5

Theoretical Analysis

MedKoo Cat#: 598045

Name: Tirofiban

CAS#: 144494-65-5

Chemical Formula: C22H36N2O5S

Exact Mass: 440.2345

Molecular Weight: 440.59

Elemental Analysis: C, 59.97; H, 8.24; N, 6.36; O, 18.16; S, 7.28

Price and Availability

Size Price Availability Quantity
5mg USD 500.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
142373-60-2 (HCl) 150915-40-5 (HCl hydrate)
Synonym
Tirofiban; MK383; MK-383; MK 383;
IUPAC/Chemical Name
(S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid
InChi Key
COKMIXFXJJXBQG-NRFANRHFSA-N
InChi Code
InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
SMILES Code
O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 440.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rizk M, El-Alamin MMA, Elkhalek OA, Hendawy HAM. Electrochemical study of anti-platelets tirofiban HCl in dosage form using nanomaterials modified sensors: developed and green assessed by eco-scale and complex-GAPI approach. BMC Chem. 2025 Jan 8;19(1):9. doi: 10.1186/s13065-024-01358-1. PMID: 39780238; PMCID: PMC11716068. 2: Yue C, Liu X, Guo C, Wang L, Zhao W, Sun W, Song J, Yang J, Li L, Yu N, Yang S, Shi X, Huang J, Kong W, Li Z, Yang S, Yang S, Zi W, Lin Y, Li F. Efficacy and safety of tirofiban in acute ischemic stroke patients with ideal reperfusion: A cohort study of LAA and CE subgroups. Eur J Neurol. 2025 Jan;32(1):e70034. doi: 10.1111/ene.70034. PMID: 39776227; PMCID: PMC11707622. 3: Wang L, Mi LY, Chen XY, He HW, Long Y. Effects of different antiplatelet therapy drugs on platelet activation and platelet-leukocyte aggregate formation in early septic ARDS. BMC Pharmacol Toxicol. 2025 Jan 6;26(1):4. doi: 10.1186/s40360-024-00806-x. PMID: 39762913; PMCID: PMC11705853. 4: Zhou D, Wu J, Wang Q, Liu Y, Wang S, Zhang W, Zhang Y, Ding H, Shao Y, Wang H, Shen Q. Miniature Mass Spectrometry for Point-of-Care Testing the GPIIb/IIIa Inhibitor Tirofiban during Perioperative Period of Percutaneous Coronary Intervention. ACS Omega. 2024 Dec 10;9(51):50326-50333. doi: 10.1021/acsomega.4c06581. PMID: 39741813; PMCID: PMC11683618. 5: Ribeiro LFS, de Freitas LR, Udoma-Udofa OC, Monteiro JDS, Silva YP, Fagundes W. Efficacy and safety of tirofiban in acute ischemic stroke due to intracranial atherosclerotic disease for patients undergoing endovascular treatment: a systematic review and meta-analysis. Neuroradiology. 2024 Dec 30. doi: 10.1007/s00234-024-03537-2. Epub ahead of print. PMID: 39739034. 6: Chen W, Chai Z, Ye Y, Xu X, Huang X, Huang R. Factors affecting the outcomes of tirofiban treatment in posterior circulation stroke. Clin Neurol Neurosurg. 2024 Dec 19;249:108694. doi: 10.1016/j.clineuro.2024.108694. Epub ahead of print. PMID: 39709746. 7: Jiao Y, Wang X, Guan Y, Wang X, Li Z, Xiang X, Zhang Z. Therapeutic Efficacy of Tirofiban Combined With Thrombus Aspiration and Stent Thrombectomy in the Treatment of Large Vessel Occlusion Ischemic Stroke. Neurologist. 2024 Dec 6. doi: 10.1097/NRL.0000000000000603. Epub ahead of print. PMID: 39648705. 8: Li L, Huang QH, Shao QJ, Chang KT, Zhang QQ, Zhu LF, Liu JM, Li TX, Gao BL. Different antiplatelet regimens for stenting versus coiling for acutely-ruptured cerebral aneurysms. Sci Rep. 2024 Dec 5;14(1):30331. doi: 10.1038/s41598-024-81792-2. PMID: 39639067; PMCID: PMC11621369. 9: Peng X, Guo C, Yang J, Fan S, Xu X, Ma J, Wang Z, Yang S, Zi W, Huang X, Wang H. Number of Retrieval Attempts and the Association of Intravenous Tirofiban with Symptomatic Intracranial Hemorrhage in Patients with Successful Endovascular Therapy: Results of the RESCUE BT Trial. Clin Interv Aging. 2024 Nov 29;19:2001-2012. doi: 10.2147/CIA.S481084. PMID: 39628662; PMCID: PMC11614580. 10: Ikramullah; Hamidullah; Ahmad F, Khan S, Bilal HA; Samiurehman. FREQUENCY OF NO-REFLOW IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION AND THE IMPACT OF INTRACORONARY ADRENALINE AND TIROFIBAN ON TIMI FLOW. J Ayub Med Coll Abbottabad. 2024 Jul-Sep;36(3):510-513. doi: 10.55519/JAMC-03-13041. PMID: 39623824. 11: Garayzade R, Berlis A, Arndt TT, Wolfert C, Sommer B, Müller G, Maurer CJ. Role and Safety of Tirofiban in Peri-Interventional Antiplatelet Management for Aneurysm Treatment. Clin Neuroradiol. 2024 Nov 28. doi: 10.1007/s00062-024-01480-6. Epub ahead of print. PMID: 39607554. 12: Foladore A, Lattanzio S, Lombardi E, Durante C, Baryshnikova E, Anguissola M, Rota L, Ranucci M, Mazzucato M. A New Shear-Stress-Based Point-of-Care Technology for Evaluation of the Hemostatic Pattern in Whole Blood. Biosensors (Basel). 2024 Oct 22;14(11):518. doi: 10.3390/bios14110518. PMID: 39589977; PMCID: PMC11592075. 13: Xie D, Wan J, Guo C, Yang J, Huang J, Peng Z, Huang J, Li L, Fan S, Yang D, Sun W, Zi W, Li F, Peng F, Hu J, Yang Q. Values of H-Type Hypertension in Patients with Large Vessel Occlusion. Clin Interv Aging. 2024 Nov 21;19:1907-1917. doi: 10.2147/CIA.S488000. PMID: 39588060; PMCID: PMC11587790. 14: Pelesz A, Rafa-Zablocka K, Kaczara P, Chlopicki S, Przyborowski K. Protein disulfide isomerase 1 (PDIA1) regulates platelet-derived extracellular vesicle release. Thromb Res. 2025 Jan;245:109209. doi: 10.1016/j.thromres.2024.109209. Epub 2024 Nov 12. PMID: 39566352. 15: Yuan X, Lu D, Xue Y, Chen L, Hu S, Wang N. Effect of tirofiban combined with endovascular treatment on hemorrhagic transformation and neurological function in patients with ischemic stroke. Am J Transl Res. 2024 Oct 15;16(10):5552-5563. doi: 10.62347/HAIW5465. PMID: 39544730; PMCID: PMC11558384. 16: Wang B, Yang Y, Ding X, Sun J, Yu W, Zhao Y, Ma Q, Yu Y. Prevention of early thrombosis in transplanted vein model by encapsulation with tirofiban microneedle drug delivery system. Biomed Mater. 2024 Nov 26;20(1). doi: 10.1088/1748-605X/ad920d. PMID: 39536450. 17: Toudou-Daouda M, Yatwa-Zaniwe RV, Aminou-Tassiou NR, Baby M, Soumah D, Altarcha T, Aghasaryan M, Laine O, Chausson N, Smadja D. Intravenous thrombolysis plus tirofiban versus tirofiban alone in Caucasian patients with acute anterior choroidal or paramedian pontine infarction. Brain Circ. 2024 Sep 26;10(3):250-256. doi: 10.4103/bc.bc_15_24. PMID: 39526109; PMCID: PMC11542752. 18: Sarraf M, Nagaraja V. The Evolving Paradigm of Intracoronary Tirofiban Administration in STEMI. Heart Lung Circ. 2024 Nov;33(11):1503-1506. doi: 10.1016/j.hlc.2024.10.004. PMID: 39521575. 19: Tao C, Liu T, Sun J, Zhu Y, Li R, Wang L, Zhang C, Song J, Jing X, Nguyen TN, Nogueira RG, Saver JL, Hu W. Advancing stroke safety and efficacy through early tirofiban administration after intravenous thrombolysis: The multicenter, randomized, placebo-controlled, double-blind ASSET IT trial protocol. Int J Stroke. 2024 Nov 20:17474930241299666. doi: 10.1177/17474930241299666. Epub ahead of print. PMID: 39501470. 20: Yang Y, Yang Q. Efficacy and safety of tirofiban plus recombinant tissue plasminogen activator versus recombinant tissue plasminogen activator alone in acute ischemic stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis. 2025 Jan;34(1):108111. doi: 10.1016/j.jstrokecerebrovasdis.2024.108111. Epub 2024 Nov 3. PMID: 39500477.